Purchase Order 75N92020P00276
Award Date 9/21/20
Potential Completion Date 1/30/21
Potential Value $59K
Funding Federal Agency
Contracting Federal Agency
Ultimate Awardee
NAICS Category
PSC Category
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
- Not listed
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Bethesda, MD 20814, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
2
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases has awarded a firm fixed price purchase order valued at $10,896 to Agilent Technologies Inc. for a one-year service contract supporting their Agilent 5300 Fragment Analyzer System. The contract will run from December 1, 2023 through December 31, 2024. Agilent Technologies Inc. will provide customer service and sales to support the genomic technology section's fragment analyzer located in...
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to Agilent Technologies Inc. for a SEAHORSE XFE96 ANALYZER 64 BIT valued at $164,253.00 on September 20, 2019. The order carries a firm fixed price and has an ultimate completion date of October 30, 2019. Place of performance is Bethesda, Maryland. The solicitation was posted on September 13, 2019, with a due date of September 18, 2019, and no set-aside was used.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued an $85,924.80 delivery order to Agilent Technologies Inc. on August 1, 2026, for maintenance of a Seahorse XFE96 Analyzer under the GSA Multiple Award Schedule (MAS).</p> <p>Place of performance is Bethesda, MD. The order extends through July 31, 2030, under firm fixed price terms with no set-aside.</p>
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a $11,448 firm fixed-price purchase order to Agilent Technologies Inc. on December 1, 2024, with performance expected to conclude by November 30, 2025. This uncompetitive, no-set-aside contract represents a child award under Agilent's broader federal contracting relationship. The work will be performed at Agilent's facility in Marshallton, Delaware, with execution by the company's Customer Service and Sales...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a $13,785.00 delivery order to Illumina, Inc. on July 15, 2020, under a firm fixed-price structure with no set-aside designation. Place of performance is Bethesda, Maryland. The order's period of performance ran from September 30, 2020, through September 29, 2021, with ultimate completion on September 2, 2020. The source does not specify the parent vehicle name or detailed scope of the delivery ordered. No...
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a delivery order to Illumina, Inc., on August 1, 2019, with a ceiling value of $146,094.39 and an ultimate completion date of September 2, 2020.</p> <p>Place of performance is Bethesda, MD. The order is priced on a firm fixed-price basis. No set-aside was used.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a purchase order to ProteinSimple for $37,250 on September 28, 2020, for acquisition of an automated immunoassay system. Place of performance is Bethesda, Maryland. The order carries a fixed-price award-fee structure with an ultimate completion date of November 30, 2020. No set-aside designation applied to this acquisition.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a delivery order to Illumina, Inc. on July 27, 2015, with a ceiling value of $89,483.32 and an ultimate completion date of August 15, 2016.</p> <p>Place of performance is Bethesda, Maryland. The order is priced on a firm fixed-price basis with no set-aside designation. The source does not identify the parent vehicle under which this delivery order was issued.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a $101,126.67 delivery order to Illumina, Inc. on January 25, 2017, with an ultimate completion date of January 24, 2018.</p> <p>Place of performance is Bethesda, MD 20892. The order is firm fixed price with no set-aside. The source does not identify the parent vehicle governing this delivery order or specify the equipment or services being procured.</p>
- <p>The National Institute of Arthritis and Musculoskeletal and Skin Diseases issued a delivery order to Illumina, Inc. on December 16, 2017, with a ceiling value of $18,744.54.</p> <p>Place of performance is Bethesda, MD 20892. The order was priced firm fixed price with no set-aside designation. Ultimate completion date is September 2, 2020.</p>